Arbutus Biopharma Says FDA Lifts Clinical Hold On AB-101 IND, Company May Now Engage In Additional Clinical Development For AB-101 In US
Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the
The FDA allowed Arbutus to test a new medicine again after pausing it. Now watch if the company reports good results from those new tests.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.